A Pilot Randomized Trial of Transdermal Nicotine for Pulmonary Sarcoidosis


      Tobacco smoking is associated with a reduced risk of developing sarcoidosis, and we previously reported that nicotine normalizes immune responses to environmental antigens in patients with active pulmonary sarcoidosis. The effects of nicotine on the progression of pulmonary sarcoidosis are unknown.

      Research Question

      Is nicotine treatment well tolerated, and will it improve lung function in patients with active pulmonary sarcoidosis?

      Study Design and Methods

      With local institutional review board approval, a randomized, double-blind, controlled pilot trial was conducted of daily nicotine transdermal patch treatment (21 mg daily) or placebo patch use for 24 weeks. The Ohio State University Wexner Medical Center and Cleveland Clinic enrolled 50 consecutive subjects aged ≥ 18 years with active pulmonary sarcoidosis, based on symptoms (ie, dyspnea, cough) and objective radiographic evidence of infiltrates consistent with nonfibrotic lung disease. Each study group was compared at 26 weeks based on repeated measures of FVC, FEV1, quantitative lung texture score based on CT texture analysis, Fatigue Assessment Score (FAS), St. George’s Respiratory Questionnaire (SGRQ), and the Sarcoidosis Assessment Tool.


      Nicotine treatment was associated with a clinically significant, approximately 2.1% (70 mL) improvement in FVC from baseline to 26 weeks. FVC decreased by a similar amount (2.2%) in the placebo group, with a net increase of 140 mL (95% CI, 10-260) when comparing nicotine vs placebo groups at 26 weeks. FEV1 and FAS improved marginally in the nicotine-treated group, compared with those on placebo. No improvement was observed in lung texture score, FAS, St. George’s Respiratory Questionnaire score, or the Sarcoidosis Assessment Tool. There were no reported serious adverse events or evidence of nicotine addiction.


      Nicotine treatment was well tolerated in patients with active pulmonary sarcoidosis, and the preliminary findings of this pilot study suggest that it may reduce disease progression, based on FVC.

      Clinical Trial Registration; No.: NCT02265874; URL:

      Graphical Abstract

      Key Words


      fas (Fatigue Assessment Score), LTS (lung texture score)
      To read this article in full you will need to make a payment
      Subscribe to CHEST
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Rahaghi F.F.
        • Baughman R.P.
        • Saketkoo L.A.
        • et al.
        Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis.
        Eur Respir Rev. 2020; 29: 190146
        • Judson M.A.
        Developing better drugs for pulmonary sarcoidosis: determining indications for treatment and endpoints to assess therapy based on patient and clinician concerns.
        F1000Res. 2019; 8 (F1000 Faculty Rev-2149)
        • Rossides M.
        • Kullberg S.
        • Eklund A.
        • et al.
        Risk of first and recurrent serious infection in sarcoidosis: a Swedish register-based cohort study.
        Eur Respir J. 2020; 56: 2000767
        • Judson M.A.
        • Chaudhry H.
        • Louis A.
        • Lee K.
        • Yucel R.
        The effect of corticosteroids on quality of life in a sarcoidosis clinic: the results of a propensity analysis.
        Respir Med. 2015; 109: 526-531
        • Cormier Y.
        • Israel-Assayag E.
        • Bedard G.
        • Duchaine C.
        Hypersensitivity pneumonitis in peat moss processing plant workers.
        Am J Respir Crit Care Med. 1998; 158: 412-417
        • Newman L.S.
        • Rose C.S.
        • Bresnitz E.A.
        • et al.
        A case control etiologic study of sarcoidosis: environmental and occupational risk factors.
        Am J Respir Crit Care Med. 2004; 170: 1324-1330
        • Valeyre D.
        • Soler P.
        • Clerici C.
        • et al.
        Smoking and pulmonary sarcoidosis: effect of cigarette smoking on prevalence, clinical manifestations, alveolitis, and evolution of the disease.
        Thorax. 1988; 43: 516-524
        • Ferrara G.
        • Murray M.
        • Winthrop K.
        • et al.
        Risk factors associated with pulmonary tuberculosis: smoking, diabetes and anti-TNFalpha drugs.
        Curr Opin Pulm Med. 2012; 18: 233-240
        • Valdez-Miramontes C.E.
        • Trejo Martinez L.A.
        • Torres-Juarez F.
        • et al.
        Nicotine modulates molecules of the innate immune response in epithelial cells and macrophages during infection with M. tuberculosis.
        Clin Exp Immunol. 2020; 199: 230-243
        • Blanchet M.R.
        • Israel-Assayag E.
        • Cormier Y.
        Inhibitory effect of nicotine on experimental hypersensitivity pneumonitis in vivo and in vitro.
        Am J Respir Crit Care Med. 2004; 169: 903-909
        • Ingram J.R.
        • Rhodes J.
        • Evans B.K.
        • Thomas G.A.
        Nicotine enemas for active Crohn's colitis: an open pilot study.
        Gastroenterol Res Pract. 2008; 2008: 237185
        • Julian M.W.
        • Shao G.
        • Schlesinger L.S.
        • et al.
        Nicotine treatment improves Toll-like receptor 2 and Toll-like receptor 9 responsiveness in active pulmonary sarcoidosis.
        Chest. 2013; 143: 461-470
        • Shao B.Z.
        • Wang S.L.
        • Fang J.
        • Li Z.S.
        • Bai Y.
        • Wu K.
        Alpha7 nicotinic acetylcholine receptor alleviates inflammatory bowel disease through induction of AMPK-mTOR-p70S6K-mediated autophagy.
        Inflammation. 2019; 42: 1666-1679
        • Zhang Q.
        • Lu Y.
        • Bian H.
        • Guo L.
        • Zhu H.
        Activation of the alpha7 nicotinic receptor promotes lipopolysaccharide-induced conversion of M1 microglia to M2.
        Am J Transl Res. 2017; 9: 971-985
        • Hade E.M.
        • Smith R.M.
        • Culver D.A.
        • Crouser E.D.
        Design, rationale, and baseline characteristics of a pilot randomized clinical trial of nicotine treatment for pulmonary sarcoidosis.
        Contemp Clin Trials Commun. 2020; 20: 100669
        • Crouser E.D.
        • Maier L.A.
        • Wilson K.C.
        • et al.
        Diagnosis and detection of sarcoidosis: an official American Thoracic Society clinical practice guideline.
        Am J Respir Crit Care Med. 2020; 201: e26-e51
        • Crapo R.O.
        • Morris A.H.
        • Gardner R.M.
        Reference spirometric values using techniques and equipment that meet ATS recommendations.
        Am Rev Respir Dis. 1981; 123: 659-664
        • Erdal B.S.
        • Crouser E.D.
        • Yildiz V.
        • et al.
        Quantitative computerized two-point correlation analysis of lung CT scans correlates with pulmonary function in pulmonary sarcoidosis.
        Chest. 2012; 142: 1589-1597
        • Michielsen H.J.
        • De Vries J.
        • Van Heck G.L.
        Psychometric qualities of a brief self-rated fatigue measure: the Fatigue Assessment Scale.
        J Psychosom Res. 2003; 54: 345-352
        • Judson M.A.
        • Mack M.
        • Beaumont J.L.
        • Watt R.
        • Barnathan E.S.
        • Victorson D.E.
        Validation and important differences for the Sarcoidosis Assessment Tool. A new patient-reported outcome measure.
        Am J Respir Crit Care Med. 2015; 191: 786-795
        • Barr J.T.
        • Schumacher G.E.
        • Freeman S.
        • LeMoine M.
        • Bakst A.W.
        • Jones P.W.
        American translation, modification, and validation of the St. George’s Respiratory Questionnaire.
        Clin Ther. 2000; 22: 1121-1145
        • du Bois R.M.
        • Weycker D.
        • Albera C.
        • et al.
        Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.
        Am J Respir Crit Care Med. 2011; 184: 1382-1389
        • Altman D.G.
        • Dore C.J.
        Randomisation and baseline comparison in clinical trials.
        Lancet. 1990; 335: 149-153
        • Kafaja S.
        • Clements P.J.
        • Wilhalme H.
        • et al.
        Reliability and minimal clinically important differences of forced vital capacity: results from the Scleroderma Lung Studies (SLS-I and SLS-II).
        Am J Respir Crit Care Med. 2018; 197: 644-652
        • Yeager H.
        • Rossman M.D.
        • Baughman R.P.
        • et al.
        Pulmonary and psychosocial findings at enrollment in the ACCESS study.
        Sarcoidosis Vasc Diffuse Lung Dis. 2005; 22: 147-153
        • Baughman R.P.
        • Shipley R.
        • Desai S.
        • et al.
        Changes in chest roentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluation.
        Chest. 2009; 136: 526-535
        • Baughman R.P.
        • Drent M.
        • Kavuru M.
        • et al.
        Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement.
        Am J Respir Crit Care Med. 2006; 174: 795-802
        • Broos C.E.
        • Poell L.H.C.
        • Looman C.W.N.
        • et al.
        No evidence found for an association between prednisone dose and FVC change in newly-treated pulmonary sarcoidosis.
        Respir Med. 2018; 138S: S31-S37
        • Spratling L.
        • Tenholder M.F.
        • Underwood G.H.
        • Feaster B.L.
        • Requa R.K.
        Daily vs alternate day prednisone therapy for stage II sarcoidosis.
        Chest. 1985; 88: 687-690
        • Pietinalho A.
        • Tukiainen P.
        • Haahtela T.
        • Persson T.
        • Selroos O.
        • Finnish Pulmonary Sarcoidosis Study Group
        Early treatment of stage II sarcoidosis improves 5-year pulmonary function.
        Chest. 2002; 121: 24-31
        • Cox C.E.
        • Donohue J.F.
        • Brown C.D.
        • Kataria Y.P.
        • Judson M.A.
        Health-related quality of life of persons with sarcoidosis.
        Chest. 2004; 125: 997-1004
        • Pujades-Rodriguez M.
        • Morgan A.W.
        • Cubban R.M.
        • Wu J.
        Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: a population-based cohort study.
        PLoS Med. 2020; 17e1003432
        • Strookappe B.
        • Swigris J.
        • De Vries J.
        • Elfferich M.
        • Knevel T.
        • Drent M.
        Benefits of physical training in sarcoidosis.
        Lung. 2015; 193: 701-708
        • Thunold R.F.
        • Lokke A.
        • Cohen A.L.
        • Ole H.
        • Bendstrup E.
        Patient reported outcome measures (PROMs) in sarcoidosis.
        Sarcoidosis Vasc Diffuse Lung Dis. 2017; 34: 2-17
        • Huang H.
        • Xu Y.
        • van den Pol A.N.
        Nicotine excites hypothalamic arcuate anorexigenic proopiomelanocortin neurons and orexigenic neuropeptide Y neurons: similarities and differences.
        J Neurophysiol. 2011; 106: 1191-1202